To the best of our knowledge, the present study is the first to report the decreased levels of CD59 in the urine of patients with ovarian cancer although similar reduced excretion of the protein had previously been reported in the urine of patients with bladder cancer [13] and pancreatic ductal adenocarcinoma [14]. Here, CD59 is linked to urinary bladder cancer.